UroGen Pharma (NASDAQ:URGN) Now Covered by Analysts at LADENBURG THALM/SH SH
Equities researchers at LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma (NASDAQ:URGN – Get Free Report) in a research note issued on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $31.00 price target on the stock. LADENBURG THALM/SH SH’s price objective suggests a potential upside of 189.45% from the […]
Equities researchers at LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma (NASDAQ:URGN – Get Free Report) in a research note issued on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $31.00 price target on the stock. LADENBURG THALM/SH SH’s price objective suggests a potential upside of 189.45% from the […]
